Table 5.
Physician-determined improvement in SLE clinical manifestations from baseline at Month 6
| Arthritis (n = 36) | Rash (n = 24) | Fatigue (n = 15) | Low complement (n = 14) | Alopecia (n = 11) | Increased anti-dsDNA antibody levels (n = 11) | Inability to taper glucocorticoids (n = 10) | Mucosal ulcers (n = 9) | Proteinuria (n = 7) | Leukopenia (n = 7) | |
|---|---|---|---|---|---|---|---|---|---|---|
| Worsened, n (%) | 0 (0) | 2 (8.3) | 0 (0) | 0 (0) | 0 (0) | 1 (9.1) | 0 (0) | 0 (0) | 1 (14.3) | 0 (0) |
| No improvement, n (%) | 1 (2.8) | 3 (12.5) | 1 (6.7) | 4 (28.6) | 3 (27.3) | 3 (27.3) | 1 (10.0) | 2 (22.2) | 3 (42.9) | 5 (71.4) |
| <20% improvement, n (%) | 3 (8.3) | 4 (16.7) | 2 (13.3) | 3 (21.4) | 1 (9.1) | 2 (18.2) | 0 (0) | 0 (0) | 1 (14.3) | 1 (14.3) |
| ≥20% improvement, n (%) | 32 (88.9) | 15 (62.5) | 12 (80.0) | 7 (50.0) | 7 (63.6) | 5 (45.5) | 9 (90.0) | 7 (77.8) | 2 (28.6) | 1 (14.3) |
| ≥50% improvement, n (%) | 25 (69.4) | 12 (50.0) | 4 (26.7) | 6 (42.9) | 6 (54.5) | 1 (9.1) | 4 (40.0) | 6 (66.7) | 1 (14.3) | 1 (14.3) |
| ≥80% improvement, n (%) | 13 (36.1) | 6 (25.0) | 0 (0) | 3 (21.4) | 1 (9.1) | 0 (0) | 3 (30.0) | 5 (55.6) | 0 (0) | 0 (0) |
Anti-dsDNA anti-double-stranded DNA, SLE systemic lupus erythematosus